# Lucentis in Advanced Macular Degeneration

> **NCT00896779** · PHASE2 · COMPLETED · sponsor: **Steven R. Sanislo** · enrollment: 20 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT00896779
- **Lead sponsor:** Steven R. Sanislo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-06-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00896779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00896779, "Lucentis in Advanced Macular Degeneration". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00896779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*